Drug Profile

BRC 001

Alternative Names: BRC-001; Cannabidiol; CBD oil; CBD-Biopharmaceutical Research Company

Latest Information Update: 20 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biopharmaceutical Research Company
Class Analgesics; Cannabinoids; Cyclohexenes; Hydroxybenzoic acids; Salicylic acids
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Feb 2025 Biopharmaceutical Research Company plans a phase III trial for Arthralgia in mid 2026
29 Jan 2025 US FDA reviews Chemistry, Manufacture and Controls (CMC) of phytocannabinoid-based therapeutics for Joint disorders
27 Dec 2024 Phase-II clinical trials in Arthralgia in USA (PO) (NCT06538389)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com